(Total Views: 335)
Posted On: 05/26/2021 9:59:35 PM
Post# of 154979
Re: chazzledazzle #91931
Moderate patients get SOC. I missed that also when I first took a look at the trials.
Quote:
This is a Phase 3, 2-arm, randomized, double blind, placebo controlled, multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) as an add on therapy to the institutional standard of care (SoC) for the management of moderately ill patients with COVID-19 pneumonia.
(0)
(0)
